REYKJAVIK, Iceland, May 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the ...

Alvotech ( NASDAQ:ALVO ) just reported some strong earnings, and the market reacted accordingly with a healthy ...

Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

Alvotech faces challenges with potential tariffs and profitability, despite strong revenue growth and a robust pipeline. See if ALVO is a buy-the-dip stock opportunity or not.

Good day, and thank you for standing by. Welcome to the Alvotech Q1 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation ...

Learn more about whether Alvotech or BioCryst Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple ...

REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines ...

It announces that Alvogen Lux Holdings S.ár.l., the second largest shareholder in Alvotech, has acquired 210,000 shares at ISK 1,277.38 each. The largest shareholders in Alvogen Lux Holdings are ...